. 2019 Nov 2;221(7):1146–1155. doi: 10.1093/infdis/jiz572

Table 2.

Changes From Baseline in the Percentage of T-Cell Subsets Expressing CD30 or Markers of T-Cell Activation and Exhaustion

	Time Point 1 to Time Point 2 [Pre-ATI to ATI (Pre-HIV Rebound)]				Time Point 1 to Time Point 3^b (Pre-ATI to Post-HIV Rebound)
Marker	Absolute Change^a	Relative Change^b	RC 95% CI^b	P ^b	Absolute Change^a	Relative Change^b	RC 95% CI^b	P ^b
%CD4⁺CD30⁺ T Cells	0.04%	1.65	1.16–2.34	.005	0.03%	1.50	1.05–2.12	.02
CD4⁺CD30⁺ MFI	21.10	1.04	0.99–1.09	.05	5.33	1.01	0.97–1.05	.66
%CD4⁺CD153⁺ T Cells	0.01%	0.98	0.74–1.29	.89	<−0.01%	0.88	0.67–1.17	.38
%CD4⁺ CD69⁺ T Cells	−0.11%	1.02	0.78–1.34	.88	0.02%	1.32	1.00–1.74	.049
%CD4⁺CD38/HLA-DR⁺ T Cells	−0.02%	1.01	0.80–1.29	.93	0.59%	1.33	1.04–1.69	.02
%CD4⁺ T_TM/T_EM⁺ T Cells	1.57%	1.06	0.93–1.20	.38	0.55%	1.05	0.93–1.19	.44
%CD4⁺PD-1⁺ T Cells	1.67%	1.07	0.94–1.23	.32	3.59%	1.20	1.04–1.37	.38
%CD8⁺CD30⁺ T Cells	−0.32%	0.73	0.30–1.76	.48	−1.00%	0.74	0.29–1.89	.53
%CD8⁺CD153⁺ T Cells	<0.01	0.64	0.35–1.18	.15	−0.07	0.47	0.24–0.91	.03
%CD8⁺CD69⁺ T Cells	0.01%	0.99	0.81–1.20	.89	0.09%	1.00	0.83–1.23	.95
%CD8⁺CD38/HLA-DR⁺ T Cells	0.61%	1.15	0.70–1.91	.58	14.77%	3.17	1.90–5.30	<.01
Cell-associated HIV-1 RNA (copies/106 CD4⁺ T cells)	17 468	2.68	0.63–11.41	.18	267 912	18.89	4.44–80.32	<.01
Cell-Associated HIV-1 DNA (copies/106 CD4⁺ T cells)	−6	0.63	0.33–1.18	.15	22	1.84	0.98–3.46	.06

Abbreviations: ATI, analytical treatment interruption; CI, confidence interval; DNA, deoxyribonucleic acid; HIV, human immunodeficiency virus; HLA, human leukocyte antigen; MFI, mean fluorescence intensity; RC, relative change; RNA, ribonucleic acid.

^aCalculated from all values for each time point (difference from pre-ATI baseline).

^bAs determined by mixed-linear effects modeling.